By Mike Basset
Risk management strategies including bilateral salpingo-oophorectomy (BSO) for ovarian cancer and MRI surveillance for breast cancer were associated with a significant reduction in mortality for women with BRCA1/2 sequence variations, according to results from two cohort studies … Read more
Clearity’s Perspective: Clearity offers emotional support to people with ovarian cancer and their caregivers through our Steps Through OC program. If you would like personal one-to-one assistance with the stress and challenges associated with an ovarian cancer diagnosis, our team … Read more
By Fay Lin, PhD
A major bottleneck in early detection is the molecular heterogeneity between ovarian cancer (OC) patients, which limits the likelihood of identifying individual biomarkers that are shared among patients. In a new study “A personalized probabilistic … Read more
By Ashling Wahner
Although the antibody-drug conjugate (ADC) mirvetuximab soravtansine-gynx (Elahere) is associated with a high rate of ocular toxicity in patients with folate receptor α (FRα)-positive, platinum-resistant ovarian cancer, the real-world incidence of this adverse effect (AE) in this … Read more
By Erin T. Welsh, MA
Asian, Black and Hispanic women with … Read more
By Rylan DeStefano
An artificial intelligence model called IRON (Integrated Radiogenomics for Ovarian Neoadjuvant therapy) shows an 80% accuracy rate in the prediction of therapy outcomes for patients with ovarian cancer. The artificial intelligence model focuses specifically on the volumetric … Read more
Clearity’s Perspective: Cancer cells that have mutations in BRCA or that are HRD-positive are not able to use the so-called homologous recombination repair pathway to fix mistakes in the cancer cell. These cancer cells become reliant on other repair pathways. … Read more
By Mary Caffrey
Delayed diagnoses. Symptoms that are dismissed or misinterpreted. Feelings of anxiety because no one can offer a clear explanation for their condition.
These are just some of the experiences of women who have low-grade serous ovarian cancer … Read more
More than 95% of BRCA1 or BRCA1 pathogenic variants would have been missed by DTC testing, largest such study showed
By Mark Fuerst
Direct-to-consumer (DTC) genetic testing has limited use as a screening tool for identifying individuals at risk of hereditary breast or ovarian cancer, especially in those of non-Ashkenazi Jewish descent, researchers reported.
Most current DTC genetic tests evaluate … Read more
By Hayden E. Klein
Patients with ovarian cancer saw a 70% improvement in overall survival (OS) 3 years after undergoing a multidisciplinary surgical approach compared with previous approaches to therapy, according to a study published in Annals of Surgical Oncology… Read more
Clearity’s Perspective: New research demonstrates how paclitaxel (Taxol), a commonly used and effective drug for OC, works by disrupting cancer cell division. This research helps us to get a better understanding of the mechanism through which paclitaxel (Taxol) destroys cancer … Read more
A new liquid biopsy test developed by researchers at USC Norris Comprehensive Cancer Center has shown promise to distinguish which pelvic masses are benign and which are tumorous, a development that could aid early diagnosis of high-grade serous ovarian carcinoma … Read more
Key Points:
The prevalence of distress among women with late-stage gynecologic cancers calls for well-designed studies to assess the safety and efficacy of psychedelics for this patient population, according to authors of a published commentary.
Psychedelics — specifically psilocybin — have shown … Read more
DNA can be damaged by toxins, radiation, or even normal cell division, but human cells must continually fix DNA breaks to survive. In cells that cannot repair DNA effectively, changes (mutations) can occur that lead to cancer.
Most cells rely … Read more
The search for preventions and cures has turned inward—focusing on the immune system to stop ovarian cancer.
Professor Paul Hertzog’s research group at Hudson Institute of Medical Research has been working to expand on their discovery of a naturally occurring … Read more
A new study describes a new diagnostic approach that could help identify the 15% of women with ovarian cancer whose tumors are intrinsically refractory to standard platinum-based therapies, the most common type of chemotherapy for the disease.
Most ovarian cancers … Read more
In Science Advances, Nagoya University scientists publish their work discovering three membrane proteins associated with ovarian cancer. The research team are hopeful that their discovery could improve approaches for detecting and diagnosing the disease.
Testing tumors with next-generation sequencing in patients with ovarian cancer can provide teams insight into targetable mutations that may affect treatment decisions, although this approach is not the current standard of care for all patients, an expert said.
In an
